Ⓐ
PeptiBrief
Endogenous peptide hormone

Adropin

An endogenous peptide associated with substrate use, endothelial function and cardiometabolic health. Most therapeutic claims remain preclinical.

Formula
C208H346N76O65S2
Molecular weight
4999.7 Da

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
2/5
Some animal evidence
1 citation
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.

Claimed uses

Mechanisms

Safety notes

There is no established clinical dosing, pharmaceutical specification or long-term safety profile for exogenous adropin. Unregulated products may be mislabelled or contaminated.

Regulation
  • Not approved as a medicine for obesity, diabetes, cardiovascular disease or performance enhancement.

References

  1. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus · 2013
  2. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism · 2008
Last reviewed
11 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.